These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9549254)

  • 1. If a patient does not respond to a full dose of fluvoxamine for at least 12 weeks, what alternatives should be considered?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549254
    [No Abstract]   [Full Text] [Related]  

  • 2. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks.
    Albert R; Ebert D
    J Clin Psychiatry; 1996 Apr; 57(4):176. PubMed ID: 8601556
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 4. Trichotilliomania responding to low-dose fluvoxamine.
    Ikenouchi-Sugita A; Yoshimura R; Ueda N; Nakamura J
    Psychiatry Clin Neurosci; 2009 Oct; 63(5):701-2. PubMed ID: 19788633
    [No Abstract]   [Full Text] [Related]  

  • 5. Fluvoxamine and mandibular dystonia.
    Chong SA
    Can J Psychiatry; 1995 Sep; 40(7):430-1. PubMed ID: 8548729
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine for COVID-19?
    Med Lett Drugs Ther; 2021 May; 63(1623):69-70. PubMed ID: 33976099
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study.
    Zohar J; Keegstra H; Barrelet L
    Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
    Joffe RT; Schuller DR
    J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
    Grimsley SR; Jann MW
    Clin Pharm; 1992 Nov; 11(11):930-57. PubMed ID: 1464219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex movement disorder associated with fluvoxamine.
    Bronner IM; Vanneste JA
    Mov Disord; 1998 Sep; 13(5):848-50. PubMed ID: 9756160
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
    Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
    Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.
    Martin A; Koenig K; Anderson GM; Scahill L
    J Autism Dev Disord; 2003 Feb; 33(1):77-85. PubMed ID: 12708582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding.
    Gentile S
    Arch Womens Ment Health; 2006 May; 9(3):158-9. PubMed ID: 16683078
    [No Abstract]   [Full Text] [Related]  

  • 16. Antisocial ideation and activities precipitated by the administration of SSRIs.
    Glancy GD
    Can J Psychiatry; 1993 Dec; 38(10):695. PubMed ID: 8313312
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
    Bondolfi G; Chautems C; Rochat B; Bertschy G; Baumann P
    Psychopharmacology (Berl); 1996 Dec; 128(4):421-5. PubMed ID: 8986013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.